Castle Creek Pharmaceuticals

18 articles about Castle Creek Pharmaceuticals

• Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science

  12/16/2019

  Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings"), a privately held company focused on developing medicine for important rare genetic disorders, today announced it has successfully completed the acquisition of Fibrocell Science, Inc., a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases.

• Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

  9/12/2019

  Castle Creek will advance multiple late-stage clinical development programs targeting epidermolysis bullosa

• 

  BioSpace Movers and Shakers, June 7

  6/7/2019

  Pharma and biotech companies strengthen their executive and leadership teams with new appointments.

• Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development

  6/3/2019

  Castle Creek Pharmaceuticals, LLC. announced the appointment of Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & Development of Castle Creek.

• Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy

  4/15/2019

  Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007,

• Tarveda Therapeutics Appoints Jeffrey Bloss, M.D. as Chief Medical Officer

  9/12/2018

  Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.

• Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex

  8/9/2018

  Castle Creek Pharmaceuticals, LLC., a US-based company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that the U.S. Food & Drug Administration (FDA) has designated as a Fast Track development program the investigation of diacerein 1%, ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

• Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

  5/16/2018

  Safety and efficacy of investigational drug is being evaluated in DELIVERS study for rare disorder that leads to extremely fragile skin.

• Castle Creek Pharma Announces Data Validating First Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplex Clinical Research

  1/15/2018

  Results are being presented at the Winter Clinical Dermatology Conference held January 12-17, 2018 at the Hyatt Regency Maui in Hawaii.

• Castle Creek Pharma Announces Hiring of Dr. Amir Tavakkol as Executive VP and Chief Development Officer

  10/30/2017

  Castle Creek Pharma today announced that Amir Tavakkol, Ph.D., has joined the company as executive VP and chief development officer who will report directly to Michael Derby, co-founder and CEO at CCP.

• Castle Creek Pharma Announces First Patient Enrolled In DELIVERS Study Of Diacerein 1% Ointment For Epidermolysis Bullosa Simplex

  6/5/2017

• Castle Creek Pharma Announces Presentation Of Phase II Clinical Data For Diacerein 1% Ointment In Treatment Of Epidermolysis Bullosa Simplex

  3/6/2017

• Castle Creek Pharma Announces License Of Exclusive U.S. Rights For Arlevert From Hennig Arzneimittel Gmbh

  12/13/2016

• Castle Creek Pharma Continues To Build Executive Team As Company Secures Funding, Positive Phase 2 Results

  11/2/2016

• Castle Creek Pharma Continues To Build Executive Team As Company Secures Funding, Positive Phase II Results

  11/1/2016

• Castle Creek Pharma Continues To Build Executive Team As Company Secures Funding, Positive Phase 2 Results

  11/1/2016

• Castle Creek Pharma Raises $48 Million In Funding From Fidelity Investments

  10/4/2016

• Castle Creek Pharma Announces Late-Breaking Results At EADV Of Phase 2 Topical Diacerein 1% Data In Patients With Epidermolysis Bullosa Simplex (EBS)

  10/3/2016